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Abstract
Introduction: The growing number of heart failure (HF) patients is becoming an
important issue in cardiology. B-type natriuretic peptide (BNP) is a recognized
marker of HF, including in patients with preserved systolic function. The TEI
index is an indicator of left ventricular function. The aim of the study was to
evaluate the relationship between BNP serum level, TEI index and the degree
of diastolic dysfunction in patients with HF symptoms and preserved systolic
function.
Material and methods: Hundred patients with arterial hypertension and
preserved systolic function were enrolled in the study. The study group consisted
of 51 individuals with impaired diastolic function and HF symptoms. Fourty-nine
hypertensive individuals without HF symptoms were assigned to the control
group. B-type natriuretic peptide and echocardiographic examination were
performed. Patients were divided into 4 subgroups – with normal diastolic
function, impaired relaxation, pseudonormalization and restriction.
Results: Median value of BNP in patients with normal diastolic function was
28.36 pg/ml, 87.10 pg/ml in patients with impaired relaxation, 212.75 pg/ml and
461.56 pg/ml in the pseudonormalization and restriction group respectively 
(p < 0.0001). The median value of the TEI index was: 0.386 in patients with
normal diastolic function, 0.507 in individuals with impaired relaxation, 0.639
and 0.725 in the pseudonormalization and restriction group respectively. All the
differences were statistically significant (p < 0.0001). A significant positive
correlation (r = 0.80, p < 0.001) between BNP and the TEI index was found.
Conclusions: In hypertensive patients with HF symptoms and preserved left
ventricular systolic function a highly significant increase in BNP serum level and in
the TEI index values related to the deterioration of diastolic dysfunction was found.
Key words: B-type natriuretic peptide, TEI index, heart failure with preserved systolic
function.
Introduction
Heart failure (HF) is becoming a more and more serious problem of
contemporary cardiology. Heart failure as an inability to maintain sufficient
cardiac output may be a result of either impaired systolic function and/or
abnormal ventricular filling. This provides the basis for distinguishing
(according to ESC guidelines) systolic heart failure and heart failure with
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Copyright © 2011 & Termedianormal ejection fraction (HFNEF). It is estimated
that 30-50% of patients with HF suffer from HFNEF
[1, 2]. The crucial feature of this kind of HF is
impaired ventricular filling resulting in maintaining
cardiac output at the expense of elevated filling
pressure. One of the most frequent causes of
HFNEF is hypertension. A fundamental mechanism
leading to heart failure development in the course
of hypertension is ventricular pressure overload.
Considering the importance of the issue, early
diagnosis is crucial for patients with HF. It is
diagnosed in the presence of coexistent heart
failure symptoms and objective features of systolic
or diastolic dysfunction. To date there is no single
test that is a diagnostic criterion for HF [3].
Echocardiography is a preferred method; bioche  -
mical markers with special regard to natriuretic
peptides, especially type B (BNP), are also of great
importance. However, in populations with low risk
of left ventricular dysfunction the determination of
these markers often gives false positive results and
requires further verification [4]. It is expected that
the evaluation of BNP together with comprehensive
echocardiographic examination will allow us to
single out individuals with cardiac output
maintained through the elevation of ventricular
filling pressure. These patients already have
symptoms of HF or are at high risk of developing
heart failure in the near future [3]. 
A quick evaluation of left ventricle function by
means of echocardiography may be done by
calculating the myocardial performance index (MPI),
also known as the TEI index, which reflects both
left ventricular systolic and diastolic function [5].
A normal TEI index should be below 0.4 and its
increasing values are related to deteriorated left
ventricular function.
The majority of studies investigating chronic
heart failure concern systolic HF, but a growing
number of patients diagnosed with HFNEF can be
observed. Therefore the present study was
designed to evaluate the relationship between BNP
serum level, echocardiographic TEI index and the
degree of diastolic dysfunction in hypertensive
patients with HF symptoms and preserved systolic
function. It was assumed that the concomitant
evaluation of these parameters may improve the
accuracy of HFNEF diagnosis. 
Material and methods
Hundred patients with hypertension diagnosed
at least 5 years earlier, sinus rhythm and preserved
systolic function (LVDd < 6.0 cm, LVEF > 45%) were
enrolled in the study. Patients with ischaemic heart
disease, systolic HF, severe valvular heart disease,
primary cardiomyopathy and constrictive pericarditis
were excluded from the study. All participants of
the study signed the informed consent form. The
study population was divided into two groups: one
with heart failure symptoms from NYHA class II to
IV (51 patients; 4 males and 47 females with a mean
age of 65.9 ±10.1 years) and a control group of 49
patients without HF symptoms. A comparative
analysis of both groups found no significant
differences in terms of age, sex, diabetes mellitus,
hyperlipidaemia, obesity, smoking or family history
of HF. All patients received optimal pharmaco  -
therapy according to valid standards. 
Venous blood samples were taken by veni  -
puncture in the antecubital region with minimal
venostasis, between 7.00 am and 9.00 am after
a 30-min rest, in a sitting position. No longer than
45 min elapsed between blood sampling and
measurement. B-type natriuretic peptide serum
level determination was performed by means of
microparticle enzyme immunoassay (MEIA) AxSYM
BNP test by the Abbott Diagnostics Division (normal
values < 100 pg/ml) [6].
Detailed echocardiographic examination using
a transthoracic 2.5 MHz probe of Vivid 7.0 (General
Electric Company) together with simultaneous ECG
recording was performed on the day of the BNP
serum level measurement. Examination comprised
mono- and two-dimensional echocardiography,
conventional and colour Doppler flow imaging
(pulsed- and continuous wave Doppler) and tissue
Doppler echocardiography. All of the chambers’
dimensions and wall thicknesses were measured.
Systolic function was evaluated both by assessment
of regional contractility disturbances and by
calculation of left ventricular ejection fraction (LVEF)
by means of the biplane Simpson method. Valvular
structure and function together with intracardiac
blood flow were also evaluated. 
After excluding left ventricular enlargement
(LVEDd ≤ 6.0 cm), contractility disturbances and
haemodynamically significant valvular disease, and
after confirming normal ejection fraction (LVEF 
≥ 45%), detailed left ventricular diastolic function
assessment together with the TEI index calculation
was performed. For diastolic function evaluation
Doppler techniques of mitral inflow and pulmonary
vein flow estimation were used together with the
tissue Doppler imaging of mitral annulus velocity,
which, according to Feigenbaum, are of the greatest
value in modern clinical practice [7]. After detailed
echocardiographic examination all patients were
divided into four groups according to the Canadian
Cardiovascular Society diastolic dysfunction
classification from 1996 (Table I) [8].
For normally distributed variables the mean
value and standard deviation were calculated. For
variables not normally distributed the median value
and lower and upper quartile were determined.
Pairs of variables were compared with the Mann-
Whitney U test. Kruskal ANOVA was used to
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compare several independent samples. To define
the relationship between the studied parameters
the Spearman correlation coefficient was calculated.
The significance level was set at p < 0.05 for all
tests. The results were worked out using StatSoft’s
Statistica 6.0.
Results
Clinical characteristics of study and control
group 
Among study participants 25 patients were in
NYHA class II, 19 patients in NYHA class III and 
7 patients in NYHA class III/IV (Table II).
Results of laboratory tests and
echocardiographic examination
The comparison of ejection fraction and diastolic
parameters calculated after echocardiographic
examination was conducted in the study and
control group. Analysis of these parameters
revealed significantly higher values of diastolic
dysfunction indices: dtE, IVRT, Ar, Ar(t)-A(t), E/E’ ratio
and TEI index together with lower values of S/D in
patients from the study group compared to
controls. Another observation worth mentioning is
the lack of a statistically significant difference in
the commonly used E/A ratio between the study
and control group. All parameters are presented in
Table III.
After echocardiographic examination patients
were divided into 4 groups depending on the degree
of diastolic dysfunction. Diastolic dysfunction was
graded according to a useful and universally applied
classification (CCS guidelines 1996) based on mitral
inflow parameters and pulmonary vein flow
evaluation (Table I). Impaired relaxation accounts
for mild diastolic dysfunction, pseudonormalisation
profile for moderate dysfunction, while restriction
corresponds to severe diastolic dysfunction
according to Canadian criteria. Along with diastolic
function deterioration a statistically significant
increase of BNP serum level (p < 0.001) and TEI
index value (p < 0.0001) was observed together
with exacerbation of heart failure symptoms
assessed with NYHA classification (Table IV).
Correlation between studied parameters
A significant positive correlation between BNP
serum levels and the TEI index with correlation
coefficient r = 0.80 (p < 0.0001) was observed in
the whole study population.
Degree of diastolic dysfunction E/A dtE S/D Ar Ar-A
Normal 1-2 150-200 ≥ 1 < 0.35 < 20
Mild (Impaired relaxation) < 1 > 200 ≥ 1 < 0.35 < 20
Moderate (Pseudonormalisation) 1-2 150-200 0.5-1 ≥ 0.35 ≥ 20
Severe (Restriction) > 2 < 150 < 0.5 ≥ 0.35 ≥ 20
E/A – ratio of early (E) to late atrial (A) mitral peak flow velocity, dtE – early mitral flow deceleration time, S/D – ratio of pulmonary venous
systolic (S) to diastolic (D) peak flow, Ar – peak reverse flow velocity at atrial contraction, Ar-A – difference between pulmonary venous and mitral
A wave duration
Table I. Canadian Cardiovascular Society diastolic dysfunction classification from 1996 
Degree of diastolic dysfunction E/A dtE S/D Ar Ar-A
Normal 1-2 150-200 ≥ 1 < 0.35 < 20
Mild (Impaired relaxation) < 1 > 200 ≥ 1 < 0.35 < 20
Moderate (Pseudonormalisation) 1-2 150-200 0.5-1 ≥ 0.35 ≥ 20
Severe (Restriction) > 2 < 150 < 0.5 ≥ 0.35 ≥ 20
Table II. Clinical profile of study and control group
Parameter Study group Control groupV alue of p
[unit]( n = 51) (n = 49)
EF [%] 60 ±5 67 ±8 NS
dtE [ms] 207 ±47 190 ±16 0.02
IVRT [ms] 106 ±23 96 ±7 0.02
E/A 0.91 ±0.55 0.95 ±0.19 NS
E’/A’ 0.68 ±0.14 1.03 ±0.32 < 0.0001
E/E’ 12.7 ±7.4 9.15 ±2.7 < 0.0001
S/D 1.1 ±0.3 1.44 ±0.2 < 0.0001
Ar [m/s] 0.31 ±0.03 0.29 ±0.02 0.0003
Ar(t)-A(t) [ms] –1.5 ±2.4 –17.01 ±1.7 < 0.0001
TEI 0.569 ±0.12 0.391 ±0.05 < 0.0001
E’/A’ – ratio of peak early to late diastolic velocity of the mitral annulus, 
E/E’ ratio of mitral peak velocity of early diastolic filling to peak early
diastolic velocity of the mitral annulus, IVRT – isovolumic relaxation
time
Table III. Comparison of echocardiographic para  -
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Discussion
An important role of neurohormonal activation
in heart failure has been emphasized in recent
years. Advanced research led to the discovery of
multiple substances whose serum levels were found
to be elevated in the course of HF. Among them
BNP seems to have an exceptional position. This
neurohormone is released from ventricular
myocardium in response to volume or pressure
overload. Its secretion is induced mainly by
myocardial wall strain or ischaemia. A lot of
randomized trials concerning mostly systolic heart
failure patients have proved that increased BNP
serum level allows for a reliable diagnosis of HF [9]. 
Markedly fewer publications concern BNP serum
level in patients with HFNEF. The majority of them
underline a statistically significant, though less
spectacular, increase of BNP concentration in
individuals with HF symptoms and left ventricular
diastolic dysfunction compared to healthy controls
[10, 11].
In The Breathing Not Properly Multinational
Study in 1,586 patients referred to hospital for
sudden dyspnoea BNP serum level was measured
together with a detailed echocardiographic exami  -
nation. Four hundred and fifty-two patients were
diagnosed with heart failure including 165 (36.5%)
with isolated diastolic dysfunction (LVEF > 45%).
Parameter [unit]D iastolic function Value of p
Normal Impaired relaxation Pseudonormalisation Restriction
(n = 46) (n = 31) (n = 16) (n = 7)
BNP [pg/ml] 28.36 ±18.17 87.10 ±37.90 212.75 ±93.02 461.56 ±202.1 < 0.0001 
TEI 0.386 ±0.035 0.507 ±0.071 0.639 ±0.094 0.725 ±0.096 < 0.0001
NYHA [%]
I9 2 8 0 0
II 8 86 6 0
III 0 6 94 0
III/IV 0 0 0 100
Table IV. Comparison of BNP serum level, TEI index between subgroups with different diastolic function profile and
distribution of patients with NYHA class I, II, III and III/IV in these subgroups
1000
800
600
400
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0
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TEI
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*
Figure 1. Correlation between BNP serum level and TEI index values in the study population
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Maisel et al. summarizing the results of the study
proved that patients with HF had higher BNP
concentration than individuals without heart failure
symptoms. Heart failure with normal ejection
fraction was, however, associated with lower BNP
serum levels than systolic dysfunction (413 pg/ml
vs. 821 pg/ml). The BNP value of 100 pg/ml allowed
for a diagnosis of systolic HF and HFNEF with 86%
and 75% sensitivity respectively [12].
Similar results were obtained by Bursi et al. after
the echocardiographic evaluation of ejection fraction
(EF) and BNP serum level measurement in 556
patients with HF. Two hundred and fourty-two
patients (44%) with isolated diastolic dysfunction
(LVEF > 50%) and significantly increased BNP level
were singled out. However, the highest BNP
concentration was observed in individuals with
diastolic dysfunction combined with reduced left
ventricular ejection fraction [13]. Parallel findings
come from other studies performed on smaller
populations in Great Britain and China [14, 15].
Tschöpe et al. conducted another study involving
patients with HF symptoms and isolated diastolic
dysfunction. The mean BNP serum level in chronic
heart failure (CHF) patients was 189.54 pg/ml and
was remarkably higher than in healthy controls –
51.89 pg/ml (p < 0.001). Moreover, a statistically
significant relationship between BNP serum level
and the degree of diastolic dysfunction evaluated
by means of echocardiography was observed.
Another correlation was found between BNP
concentration and end-diastolic left ventricular
pressure measured invasively. The authors also
emphasized the high negative predictive value
(94%) of BNP serum level determination for the
diagnosis of HF [16]. 
Recent reports also underline the remarkable
value of BNP serum level determination for
diagnosis and evaluation of disease advancement
in patients with HF including those with preserved
systolic function [17, 18]. 
The results of all the above-mentioned research
are in concordance with the present study, whose
significant finding is that BNP serum level is
markedly elevated in patients with HF symptoms
and preserved systolic function and that the
elevation is proportional to the intensity of diastolic
dysfunction in echocardiography. It is probably
because increasing diastolic dysfunction is
associated with increasing left ventricle volume
overload. Contrary observations were made by
Dahlström, who found only insignificant differences
in BNP serum levels between patients with mild
diastolic dysfunction evaluated by means of
echocardiography and individuals with normal
diastolic function. The dissimilar findings may be
a result of a different study population as Dahlström
enrolled asymptomatic patients or individuals with
symptoms non-specific for HF [19]. 
Lukowicz et al. investigating a group of 1,678 pa  -
tients found statistically significant differences in
BNP serum level between patients with diastolic
dysfunction and healthy controls (20.3 ±4.7 pg/ml
vs. 9.6 ±0.5 pg/ml, p < 0.001). At the same time more
pronounced elevation was observed in individuals
with myocardial hypertrophy (37.3 ±49.1 pg/ml,
p < 0.001). It was underlined that the more
advanced the diastolic dysfunction, the more
increased BNP concentration was noted. The
authors also emphasize that BNP level within the
normal range allows one to exclude diastolic
dysfunction and concomitant myocardial hyper  -
trophy with 99.9% probability. However, there were
also a few cases with very low BNP concentration
(9.7 ±1.7 pg/ml) in spite of the impaired relaxation
on echocardiography [20]. It could be a result of
conducting the study in a general population
without regard to their symptoms. In this context,
it is worth mentioning that in our study the
investigated group was divided according to the
presence of HF symptoms. 
The present study proved that increasing
diastolic dysfunction is associated with more severe
heart failure symptoms assessed by means of
NYHA classification. Among individuals with
impaired relaxation the majority of patients were
in NYHA class II (86%), in the pseudonormalisation
group most patients were in NYHA class III (94%),
while restriction was associated with the most
severe heart failure – all patients were in NYHA
class III/IV (100%). A statistically significant increase
of TEI index and BNP serum level connected with
more advanced heart failure should also be
underlined. Similar findings were reported by
Wieczorek et al., who determined BNP serum level
in 1050 patients with HF symptoms and healthy
volunteers in order to define the threshold value
for heart failure. In healthy participants the mean
BNP value was 9.29 pg/ml, in patients with HF
symptoms BNP serum level depended on NYHA
class and came to 83.1 pg/ml (49.4-137 pg/ml) in
NYHA class I, 235 pg/ml (137-391 pg/ml) in NYHA II,
459 pg/ml (200-871 pg/ml) in NYHA III and 1119 pg/ml
(728-1300 pg/ml) in NYHA class IV. Setting the
criterion for heart failure diagnosis at 100 pg/ml the
authors reported 82% sensitivity and 99% speci  -
ficity [21]. In this study, however, there was no
distinction between patients with systolic heart
failure and HFNEF. A correlation between BNP serum
level and NYHA functional class was also docu  -
mented by Caboral et al. The authors also indicated
the possibility for monitoring results of ambulatory
treatment of HF patients by means of BNP
determination, since it seems to be a more objec  -
tive indicator of clinical state than NYHA classi  -
fication [22].
Parthenakis et al. evaluated the TEI index and
other echocardiographic indices of left ventricular454 Arch Med Sci 3, June / 2011
function together with maximal oxygen uptake in
ergospirometry in 42 heart failure patients in NYHA
class II to IV and with LVEF < 40%. The investigators
proved that the more advanced the heart failure
assessed by NYHA classification, the higher the TEI
index (0.59 ±0.1 in NYHA class II and 1.06 ±0.24 in
NYHA class III/IV) – all differences were statistically
significant at p < 0.001 [23]. 
The TEI index is defined as the ratio of iso  -
volumic contraction time plus isovolumic relaxation
time to left ventricular ejection time and is a useful
non-invasive parameter of global, both systolic and
diastolic, left ventricular function. Its most pro  -
minent values are reproducibility, simplicity of the
measurement and independence of heart rate,
blood pressure or pre-load. It was proved in multiple
clinical trials that the TEI index is strongly positively
correlated with ejection fraction and left ventricu  -
lar end-diastolic pressure in patients with heart
failure [24]. 
The present study indicates a statistically signi  -
ficant elevation of the TEI index in HF patients with
normal EF, which was more distinct in patients with
more advanced diastolic dysfunction. This is in
concordance with the findings of Zhang et al. from
a study evaluating E/A, dtE, TEI index and
haemodynamic indices from heart catheterisation.
The authors described a positive correlation
between TEI index and left ventricular mean
diastolic pressure (LVMDP; r2 = 0.63, p < 0.0001).
TEI index ≥ 0.65 had 82% sensitivity and 96%
specificity in diagnosing pseudonormalisation or
restriction [25]. Similarly, other authors have noted
significantly higher values of TEI index in patients
with more advanced diastolic dysfunction [26, 27].
The usefulness of the TEI index in the asses  -
sment of diastolic dysfunction was also a subject
of an investigation conducted by Bruch et al. They
performed echocardiographic exa  mination with TEI
index calculation in 107 study participants – 
36 healthy volunteers, 36 patients with normal
systolic function and 35 individuals with systolic-
diastolic heart failure. TEI index values were
significantly higher in patients with diastolic
dysfunction compared to healthy controls 
(0.53 ±0.14 vs. 0.39 ±0.07, p < 0.05). The highest
levels of TEI index were observed in patients with
systolic-diastolic HF (0.94 ±0.43, p < 0.01) [28].
In the present study increased TEI index was
noted in early stages of diastolic dysfunction, which
correlated positively with other parameters of left
ventricular diastolic function. It is probably
connected with prolonged isovolumic diastole –
a “diastolic” component – in patients with impaired
relaxation of the left ventricle. It cannot be excluded
that a statistically significant increase of the TEI
index in patients with more advanced diastolic
dysfunction may be partially a result of latent
systolic dysfunction. In the studied population there
was no confirmed systolic dysfunction and LVEF
was within the normal range. However, with regard
to frequent left ventricular hypertrophy in this group
of patients this mechanism seems highly plausible.
In our study there is a strong positive correlation
between BNP serum level and the TEI index value
(r = 0.80, p < 0.0001). This relationship may be
a result of increasing pressure load of the left
ventricle in patients with more advanced diastolic
dysfunction associated with growing end-diastolic
pressure leading to BNP hypersecretion. Moreover,
a plausible mechanism related to latent systolic
dysfunction should also be considered, as it also
contributes to increase of both TEI index and BNP
serum level. 
Similar results were reported by Tanabe et al.,
who measured BNP serum concentration in 
74 patients with various cardiovascular conditions
and correlated the values with the echocar  -
diographic TEI index. Both BNP and TEI index values
were markedly increased in the group with
confirmed diastolic dysfunction compared to those
without diastolic impairment. The highest levels of
both studied parameters were found in patients
with systolic HF (LVEF < 50%). In patients with 
TEI ≥ 0.45 the BNP serum level was significantly
increased compared to individuals with TEI < 0.45
(241.4 ±451.2 pg/ml vs. 65.9 ±81.8 pg/ml, p < 0.05)
and inversely, in a group with BNP ≥ 73 pg/ml TEI
index values were significantly higher compared to
patients with BNP < 73 pg/ml (0.57 ±0.24 vs. 0.46
±0.17, p < 0.05) [29].
Okawa et al. reported significantly higher TEI
index values in patients with hypertrophic
cardiomyopathy compared to the control group
(0.55 ±0.12 vs. 0.36 ±0.08, p < 0.0001). They also
found a positive correlation between TEI index and
BNP serum level (r = 0.61, p < 0.0001). In multi-
regression analysis TEI index and E/A turned out to
be independent predictors of increased BNP serum
level [30].
It should be underlined that in the literature
there are only a few analyses of the relationship
between BNP serum concentration and echo  -
cardiographic parameters including the TEI index in
patients with HFNEF. Our study proved a strong
positive correlation between these parameters. The
remarkable diagnostic value of BNP serum level
determination and TEI index calculation in patients
with diastolic dysfunction may be an important hint
for clinicians to use concomitant measurement of
these parameters in order to improve the accuracy
of HFNEF diagnosis, especially in the early
oligosymptomatic stages of the disease. Moreover,
with regard to the fact that the TEI index is
a parameter reflecting both systolic and diastolic
function, and splitting these components is difficult,
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it may be treated as a screening test allowing for
identification of patients with marked left
ventricular dysfunction. In these patients, with
preserved systolic function and elevated TEI index,
latent systolic dysfunction should also be
considered. The present study is an attempt to
create a simple algorithm for early and objective
diagnosis of heart failure, including HF with
preserved systolic function, that could improve
treatment of patients in this asymptomatic stage
of the disease.
In conclusion, in hypertensive patients with heart
failure symptoms and preserved left ventricular
systolic function a statistically significant increase
of BNP serum level and the TEI index occurs along
with the deterioration of left ventricular diastolic
function on echocardiography. B-type natriuretic
peptide concentration and TEI index values in
patients with diastolic HF are strongly positively
correlated with each other. Concomitant measure  -
ment of these parameters may constitute
a valuable supplement to routine examinations in
patients with HF symptoms and preserved systolic
function and considerably improve the accuracy of
diastolic heart failure diagnosis.
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